You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

PERMITIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Permitil, and when can generic versions of Permitil launch?

Permitil is a drug marketed by Schering and is included in three NDAs.

The generic ingredient in PERMITIL is fluphenazine hydrochloride. There are nineteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the fluphenazine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Permitil

A generic version of PERMITIL was approved as fluphenazine hydrochloride by FRESENIUS KABI USA on April 16th, 1987.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PERMITIL?
  • What are the global sales for PERMITIL?
  • What is Average Wholesale Price for PERMITIL?
Summary for PERMITIL
Drug patent expirations by year for PERMITIL
Recent Clinical Trials for PERMITIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Canadian Institutes of Health Research (CIHR)Phase 2
Centre for Addiction and Mental HealthPhase 2

See all PERMITIL clinical trials

US Patents and Regulatory Information for PERMITIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering PERMITIL fluphenazine hydrochloride CONCENTRATE;ORAL 016008-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Schering PERMITIL fluphenazine hydrochloride TABLET;ORAL 012034-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Schering PERMITIL fluphenazine hydrochloride TABLET, EXTENDED RELEASE;ORAL 012419-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.